Our goal is to make biological drugs accessible

Biological drugs have revolutionized the treatment of many serious diseases such as cancer, rheumatoid arthritis, psoriasis and macular degeneration. The only problem is that they are so expensive that only a fraction of those affected can be treated with them. Our goal is to make biological drugs accessible to everyone who needs them.

We strive towards the lowest possible production cost

We base the development of our Biosimilars on the patented platform technology that can provide up to 12 times productivity and thereby up to an 80% cost reduction compared to standard systems in the development of biological drugs.

We are building a world-leading biosimilar developer

We develop biosimilars in treatment of macular degeneration ( Xlucane™), rheumatoid arthritis and psoriasis (BIIB801) and cancer (Xdivane™) addressing originator sales of over SEK 100 billion

0

Employees

0

Patents and patent applications

0

Biosimilars under development

Capital Markets Day 22 September, 2022


Capital Markets Day 17 May, 2021


At Xbrane Biopharma


Press Releases

11 Nov 2022

STADA and Xbrane secure EU approval for Ximluci® (ranibizumab) biosimilar referencing Lucentis®

31 Oct 2022

Change of number of shares and votes in Xbrane

28 Oct 2022

Presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

28 Oct 2022

Xbrane Biopharma releases interim report for January – September 2022

26 Oct 2022

Invitation to presentation of Xbrane Biopharma’s interim report January – September 2022 on October 28, 2022

20 Oct 2022

Xbrane Biopharma presents Nomination Committee

18 Oct 2022

Xbrane has carried out a directed share issue raising gross proceeds of approximately SEK 170 million

18 Oct 2022

Xbrane announces intention to carry out a directed share issue

19 Sep 2022

By reason of the imminent launch of Ximluci® in Europe, Xbrane Biopharma AB invites to a Capital Markets Day on September 22, 2022